NOMA earnings analysis
What we found in NOMA's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The extracted 10-Q does not include the financial statements or MD&A, so current-quarter revenue, margins, EPS, balance-sheet changes, and cash flow cannot be assessed from the provided text. The filing highlights a financing need, with up to $2,283,800 of stock issuance and a $570,950 initial closing, but also points to potential dilution. Sentiment is bearish because management reported ineffective disclosure controls as of June 30, 2026 and identified material weaknesses in financial-close and reporting oversight. The company reported no material changes to the risk factors in its 2025 Annual Report.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Committed $2.28M Equity Financing
- The company entered into a July 2026 securities purchase agreement for up to $2,283,800 of Class A common stock at $3.65 per share, representing approximately 625,699 shares.
- Initial $571K Closing Completed
- The initial financing closing on July 29, 2026 raised $570,950. Six additional closings of $285,475 each are scheduled through January 3, 2027, subject to customary conditions.
- Control Remediation Underway
- The company states that it is undertaking initiatives to remediate internal-control weaknesses, with remediation efforts ongoing as of June 30, 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Material Control Weaknesses
- Management concluded that disclosure controls and procedures were not effective as of June 30, 2026, citing material weaknesses including insufficient internal review and monitoring of the financial close and reporting process.
- Potential Equity Dilution
- The July 2026 Offering could issue approximately 625,699 shares for aggregate proceeds of up to $2,283,800, creating meaningful potential dilution to existing holders.
- Dependence on Future Financing Closings
- The offering limits the investor's beneficial ownership to 9.99% of outstanding common stock, while subsequent tranches of $285,475 are scheduled through January 3, 2027 and remain subject to closing conditions, creating ongoing financing-execution risk.
What they said about what is next.
No quantitative revenue or EPS guidance was provided in the extracted 10-Q. The filing discusses financing through the July 2026 Offering but does not provide an operating outlook.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 15, 2026
- Nomadar Corp. reported a significant increase in revenue for Q1 2026, totaling $403,800, up 116% from $186,937 in Q1 2025. However, the company reported a net loss of $1,586,954, markedly higher than the previous year's…
- 10-K · March 31, 2026
- Nomadar Corp. (NOMA) reported a significant increase in revenues for the year ended December 31, 2025, totaling $921,940, compared to just $8,025 in 2024, driven largely by its High Performance Training (HPT) program…
- 10-Q · November 21, 2025
- Nomadar Corp. reported a revenue increase of 77% year-over-year, generating $877,669 for the nine months ending September 30, 2025. However, the company also experienced significant net losses of $1.41 million due to…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing NOMA makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever